Translate this page into:
Mini Symposium on Changing Landscape: Editorial
doi:
10.4103/2278-330X.103708
Using p53 to help diagnose ovarian cancer
1
Department of medical oncology, SL Raheja Hospital, A Fortis Associated Hospital, Mumbai
*Corresponding author: Dr. Shweta Bansal. doc.shwetabansal@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Choudhary M, Goyal S, Pujani M, et al. A cytohistological study of p53 over expression in ovarian neoplasms. South Asian J Cancer 2012; 2: 58-61.
- Bode AM. Too much of a good thing? Trends Endocrinol Metab 2002;13:139-40.
- Vousden KH, Lu X. Live or let die: The cell′s response to p53. Nat Rev Cancer 2002;2:594-604.
- Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002;415:45-53.